menu
    • menu
    [{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Faes Farma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Dr. Falk Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rising Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||Cyclooxygenase | Peroxisome proliferator-activated receptor gamma | Arachidonate 5-lipoxygenase||Prostaglandin\/leukotriene","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rising Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Rising Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rising Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Anbison","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Mesalazine","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Anbison","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbison \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Anbison \/ Ethypharm"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"||Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Polyunsaturated fatty acid 5-lipoxygenase; Peroxisome proliferator-activated receptor gamma; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Inhibitor of nuclear factor kappa-B kin","graph1":"Immunology","graph2":"Phase IV","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Ferring Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Delzicol (TN)

    Menu

    Delzicol (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 07, 2022

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rising Pharmaceuticals Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Rising Pharmaceuticals Inc

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg

                            Details : Mesalamine is a small molecule drug, prostaglandin and leukotriene inhibitor, indicated for the treatment of ulcerative proctitis.

                            Product Name : Mesalamine-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 16, 2025

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

                            Details : Asacol HD-Generic (mesalamine) is an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults.

                            Product Name : Asacol HD-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 19, 2025

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Anbison

                            China arrow
                            EPSC
                            Not Confirmed

                            Anbison

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Ethypharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

                            Details : The acquisition will enable Ethypharm a full portfolio of Mesalazine forms, including a suppository form of Etiasa (mesalazine), used to treat IBD such as ulcerative colitis and Crohn's disease.

                            Product Name : Etiasa

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 13, 2024

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Ethypharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Faes Farma

                            Spain arrow
                            EPSC
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 19, 2023

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP

                            Details : Mesalamine, also known as 5-aminosalicylic acid extended-release capsule is a small molecule, which is indicated for the maintenance of remission of ulcerative colitis in adults.

                            Product Name : Apriso-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 21, 2023

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Belgian Inflammatory Bowel Disease Research and Development

                            Country arrow
                            EPSC
                            Not Confirmed

                            Belgian Inflammatory Bowel Disease Research and Development

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 15, 2023

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Ferring Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Dr. Falk Pharma

                            Germany arrow
                            EPSC
                            Not Confirmed

                            Dr. Falk Pharma

                            Germany arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Zydus Lifesciences

                            India arrow
                            EPSC
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Cadila Receives US FDA Approval for Mesalamine ER Capsules

                            Details : Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 13, 2021

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Zeria Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed

                            Zeria Pharmaceutical

                            Japan arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical

                            Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 02, 2020

                            Lead Product(s) : Mesalazine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth